Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Director departure
Ocugen, Inc. (HSGX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials"
08/22/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "MODIFIER GENE M GENE M"
08/21/2023 8-K Quarterly results
Docs: "Ocugen Provides Business Update with Second Quarter 2023 Financial Results"
08/15/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/25/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Underwriting Agreement",
"11 Great Valley Parkway"
05/05/2023 8-K Quarterly results
05/05/2023 8-K Quarterly results
04/14/2023 8-K Quarterly results
03/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION",
"Courageous Innovation March 2023 NASDAQ: OCGN Forward Looking Statements 2 This"
03/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
03/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
02/28/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results",
"Full Year 2022 Business Update February 28, 2023 NASDAQ:OCGN"
02/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION",
"Courageous Innovation February 2023 NASDAQ: OCGN Forward Looking Statements 2 This"
01/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION",
"Courageous Innovation January 2023 NASDAQ: OCGN Forward Looking Statements 2 This"
01/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met"
12/16/2022 8-K Quarterly results
11/08/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION",
"Courageous Innovation November 2022 NASDAQ: OCGN Forward Looking Statements 2 This"
11/08/2022 8-K Quarterly results
Docs: "Ocugen Provides Business Update & Third Quarter 2022 Financial Results",
"Q3 2022 Business Update November 8, 2022 NASDAQ:OCGN"
11/01/2022 8-K Quarterly results
09/28/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION"
09/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "OCUGEN ANNOUNCES PUBLICATION OF A COMPREHENSIVE REVIEW OF BBV152 IN FRONTIERS IN IMMUNOLOGY"
08/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION",
"Courageous Innovation August 2022 NASDAQ: OCGN Forward Looking Statements 2 This"
08/17/2022 8-K Quarterly results
08/16/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
04/20/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION",
"Courageous Innovation April 2022 NASDAQ: OCGN Forward Looking Statement 2 This"
04/18/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "FORM 8-K"
04/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ MALVERN, Pa., April 12, 2022 – Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, announced that the Company was informed by the U.S. Food and Drug Administration that the agency placed its Phase 2/3 immuno-bridging and broadening study for COVAXIN™ , OCU-002, on clinical hold. This is a result of the Company’ s decision to voluntarily implement a temporary pause in dosing participants of OCU-002 while it evaluates statements made by the World Health Organization following their inspection of Bharat Biotech International Limited’ s manufacturing facility. We will work with the FDA to address any questions. Ocugen, Inc. is a ..."
04/04/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION",
"Courageous Innovation March 2022 NASDAQ: OCGN Forward Looking Statement 2 This"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy